Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis B vaccines.

Daniel Shouval1

  • 1Hadassah Medical Organization, Hadassah University Hospital, 91120 Jerusalem, Israel. shouval@cc.huji.ac.il

Journal of Hepatology
|January 8, 2004
PubMed
Summary
This summary is machine-generated.

Yeast-derived hepatitis B vaccines are safe and effective for preventing hepatitis B virus infection in all age groups. New pre-S/S vaccines show promise for faster immune response in high-risk populations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Viral Hepatitis Prevention Board (VHPB) supports the continued recommendation for universal hepatitis B vaccination of all newborns within 24 hours of birth.

Human vaccines & immunotherapeutics·2025
Same author

Longterm Outcome of Therapeutic Vaccination with a Third Generation Pre-S/S HBV Vaccine (PreHevbrio<sup>R</sup>) of Chronically HBV Infected Patients.

Journal of personalized medicine·2024
Same author

Hepatitis A virus infection.

Nature reviews. Disease primers·2023
Same author

A tribute to Professor Peter Ferenci (1948-2023).

Journal of hepatology·2023
Same author

Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries.

Journal of hepatology·2023
Same author

Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.

Journal of hepatology·2022
Same journal

Reply to "Role of HBV genotype, monitoring, and events after cessation of nucleos(t)ide analogue therapy".

Journal of hepatology·2026
Same journal

When Biology Pushes Back: Lessons From HBsAg-Targeting Therapies in Hepatitis Delta.

Journal of hepatology·2026
Same journal

Moving Too Fast? A Meta-Analysis Calls for Caution on TNF Inhibitors as First-Line Therapy for Autoimmune Hepatitis.

Journal of hepatology·2026
Same journal

Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44<sup>+</sup>pDC crosstalk.

Journal of hepatology·2026
Same journal

Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration.

Journal of hepatology·2026
Same journal

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.

Journal of hepatology·2026
See all related articles

Area of Science:

  • Vaccinology
  • Hepatology
  • Immunology

Background:

  • Hepatitis B virus (HBV) infection poses a significant global health burden.
  • Effective vaccination is crucial for preventing HBV transmission and chronic liver disease.
  • Yeast-derived vaccines are a cornerstone of current HBV prevention strategies.

Purpose of the Study:

  • To evaluate the immunogenicity, safety, and cost-effectiveness of yeast-derived hepatitis B vaccines.
  • To explore the potential of novel pre-S/S hepatitis B vaccines for enhanced seroconversion.

Main Methods:

  • Review of existing data on yeast-derived small HBV envelope protein (SHB-Ag) vaccines.
  • Analysis of clinical trial outcomes for newly developed pre-S/S hepatitis B vaccines.

Related Experiment Videos

Main Results:

  • Yeast-derived SHB-Ag vaccines demonstrate strong immunogenicity, safety, and cost-effectiveness in neonates, children, and adults.
  • Newly developed pre-S/S hepatitis B vaccines show potential for rapid and augmented seroconversion rates.

Conclusions:

  • Yeast-derived hepatitis B vaccines remain a reliable and economical choice for widespread HBV prevention.
  • Pre-S/S hepatitis B vaccines represent a promising advancement for specific high-risk populations requiring a faster immune response.